Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Lenvatinib + RFA for Recurrent HCC
NCT05162898Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Henan Cancer Hospital. Primary endpoint: Recurrence-free survival time at 36 months. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
toripalimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05162898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162898.